COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL

Glofitamab plus R-CHOP in patients with high-risk LBCL: a Phase II trialПодробнее

Glofitamab plus R-CHOP in patients with high-risk LBCL: a Phase II trial

Preliminary results from NP40126: Glofitamab and R-CHOP in NHLПодробнее

Preliminary results from NP40126: Glofitamab and R-CHOP in NHL

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCL

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapy

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCLПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCL

Michael Dickinson, MBBS, DMedSc, on a Phase Ib Trial of Glofitamab Plus Pola-R-CHP in DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase Ib Trial of Glofitamab Plus Pola-R-CHP in DLBCL

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCL

How the treatment landscape of DLBCL is changing: R-CHOP vs pola-R-CHPПодробнее

How the treatment landscape of DLBCL is changing: R-CHOP vs pola-R-CHP

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?Подробнее

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?

Glofitamab step-up dosing in R/R MCLПодробнее

Glofitamab step-up dosing in R/R MCL

Glofitamab and obinutuzumab in r/r MCLПодробнее

Glofitamab and obinutuzumab in r/r MCL

Glofitamab and polatuzumab vedotin in DLBCLПодробнее

Glofitamab and polatuzumab vedotin in DLBCL

Bispecific antibodies in NHL: current insights and ongoing studiesПодробнее

Bispecific antibodies in NHL: current insights and ongoing studies

Smart Stop: Moving away from R-CHOP in DLBCLПодробнее

Smart Stop: Moving away from R-CHOP in DLBCL

Dr. Tilly Discusses Study of POLA-R-CHP in DLBCLПодробнее

Dr. Tilly Discusses Study of POLA-R-CHP in DLBCL

Pola-R-CHP vs R-CHOEP in young patients with high-risk DLBCLПодробнее

Pola-R-CHP vs R-CHOEP in young patients with high-risk DLBCL

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphomaПодробнее

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphoma

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

Glofitamab in R/R DLBCL: updated safety and efficacy data

POLARIX trial: Is Pola-R-CHP effective and safe in elderly patients with DLBCL?Подробнее

POLARIX trial: Is Pola-R-CHP effective and safe in elderly patients with DLBCL?

POLARIX Trial and Polatuzumab in Frontline Chemotherapy for DLBCL - 2024 Blood Cancer OncTalkПодробнее

POLARIX Trial and Polatuzumab in Frontline Chemotherapy for DLBCL - 2024 Blood Cancer OncTalk